

Name : Miss. Tripti Jha

Age: 35 Y

UHID:SCHI.0000016666

Address: B 284/5 chattarpur

Plan

Sex: F

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

Bill No: SCHI-OCR-8783

INDIA OP AGREEMENT

Date : 09.12.2023 11:31

OP Number: SCHIOPV23796

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TI	MT - PAN INDIA - FY2324
	URINE GLUCOSE(FASTING)	
2	2 GAMMA GLUTAMYL TRANFERASE (GGT)	
	3 SONO MAMOGRAPHY - SCREENING	
9	4 HbA1c, GLYCATED HEMOGLOBIN	
	5 LIVER FUNCTION TEST (LFT)	
	6 X-RAY CHEST PA	
	7 GLUCOSE, FASTING	
	8 HEMOGRAM + PERIPHERAL SMEAR	
	9 ENT CONSULTATION	
1	0 CARDIAC STRESS TEST(TMT)	
1	FITNESS BY GENERAL PHYSICIAN	
1	2 GYNAECOLOGY CONSULTATION	
1	3 DIET CONSULTATION	
1	4 COMPLETE URINE EXAMINATION	
1	5 URINE GLUCOSE(POST PRANDIAL) ,	
1	6 PERIPHERAL SMEAR	
_1	7 ECG	
1	8 BLOOD GROUP ABO AND RH FACTOR	
1	9 LIPID PROFILE	
2	0 BODY MASS INDEX (BMI)	
2	1 LBC PAP TEST- PAPSURE	
2	2 OPTHAL BY GENERAL PHYSICIAN 🗸	
2	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
2	4 ULTRASOUND - WHOLE ABDOMEN , \	
2	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
	6 DENTAL CONSULTATION V	
2	7 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) . う 'ゥς	

5/9/1988

Tu M Tu M 325 Captin break BP: 116/86 P: 95 b/nis HT: 151 WH: 59 Snoz: 904.

PHC Desk

From:

noreply@apolloclinics.info

Sent:

08 December 2023 12:02

To:

ankita.pragati.jha12@gmail.com

Cc:

phc.klc@apollospectra.com; syamsunder.m@apollohl.com;

cc.klc@apollospectra.com

Subject:

Your appointment is confirmed



Dear Tripti Jha.,

Greetings from Apollo Clinics,

Your corporate health check appointment is confirmed at SPECTRA NEHRU ENCLAVE clinic on 2023-12-09 at 09:45-10:00.

Payment Mode	Credit
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN INDIA OP AGREEMENT
Package Name	[ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324]

"Kindly carry with you relevant documents such as HR issued authorization letter and or appointment confirmation mail and or valid government ID proof and or company ID card and or voucher as per our agreement with your company or sponsor." Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.



भारत सरकार Government of India



तृप्ति झा Tripti Jha जन्म तिथि/ DOB: 05/09/1988 महिला / FEMALE



9781 3110 7964

मेरा आधार, मेरी पहचान



सारतीय विशिष्ट पहचान प्राधिकरण Unique Identification Authority of India

पताः

पताः आत्मजाः मंगनू झा, 1810/2, ज्ञानी बाज़ार, डीडीए पार्क के पास, उदय चन्द मार्ग, साउथ एक्सटेन्शन पार्ट-1, एंड्रूस गंज, दक्षिण दिल्ली, दिल्ली - 110049

Address: D/O: Mangnu Jha, 1810/2, Gyani Bazaar, Near DDA Park, Uday Chand Marg, South Extension Part-1, Andrewsganj, South Delhi, Delhi - 110049

9781 3110 7964





WWW

LMP - 20/11/23 Specialists in Surgery ML - 3 4 M Triph Tha 9.12.23. Lactacye - Clingen rap X~V 9971570792 DR. RUCHI TANDON

DR. (Pof.) Ameet Kishore SENIOR CONSULTANT SURGEON MBBS,(AFMC), FRCS(Glass), FRCS(Edin), FRCS-ORL(UK) ollo Spectra Ear, Nose, Throat & Neuro-Octology HOSPITALS 34/R For Appointment: +91 1140465555 Specialists in Surgery M: +91 9910995018 09:12.2023 **DR. Sharad Nair** MBBS,MS,(ENT),FHNORS **CONSULTANT SURGEON** Ear, Nose, & Throat Head, Neck & Cancer Surgery For Appointment: +91 1140465555 M: +91 9910995018 Helegy H DR. Ashwani Kumar Routini Cheen copo MBBS, DNB, MNAMS CONSULTANT SURGEON Ear, Nose, & Throat Surgery Allergy Specialist - Intermittent Nasal Blickage For Appointment: +91 1140465555 M: +91 9910995018 Non. Right Im (F) Ear B/L WAX (P) NACOWASH KIT 10gust 1 +12 Free Ar Ms. 1 Pref firm daily
HIR ymm
Tas Monten LC 195 0 K5d

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

01-419118600

Apollo Specialty Hospital Pvt. Ltd.

CIN - U85100TG2009PTC099414 **Regd. Office:** 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040-4904 7777 | www.apollohl.com

09/12/2)

Mr-Topti Tha.



marated)

Jo- VIJ

115 WW - FT

Ref of 40:25/- 0-418 10 - co/6

Bed of to. De sal

Oder para dos ver

Jugat would

Ady-Conhace

Lang

More gale good

505 (DE)

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048
Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



09/12/2023.

Miss Teipti Tha, 35 Years / Female.

C/C!- Regular Devilat Oheck up.

M/H!- N.R.

PDH: - RCT & Cooron in upper front region

since 7 - 8 years

o € !- · Stains prusud -

· tramel Hypoplasia

Greneralised Eussian & Allestion pusal.

Advised: . Scaling

: Verneurs 321 123_

- Night Grand (Soft)

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

		ID: 16666 09-12-2023 13:16:20 Tripti jha HR Female 35Ycars P Req. No. : PR Req. No. : QRS QRS : 346/449 P/QRS/T : 52/64/22 RV5/SV1 : 0.676/0.4
		3:16:20 101 bpm Diagnosis Information: 81 ms Sinus Tachycardia 116 ms Short PR Interval 75 ms 346/449 ms 52/64/22 ° 0.676/0.492 mV Report Confirmed by:
W6 W6	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Ę Z



NAME:	TRIPTI	AGE/SEX:	35	YRS./F
UHID:	1666			
REF BY:	APOLLO SPECTRA	DATE:-	09.12	.2023

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 7.4 x 4.3 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 8.4 mm

Both ovaries are normal in size ,shape and echotexture.

Right ovary: 2.8 x 1.7 cm Left ovary: 2.9 x 1.8 cm

No obvious adenexal mass is seen. No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY.

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA CONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



NAME:	TRIPTI	AGE/SEX:	35	YRS./F
UHID:	1666			
REF BY:	APOLLO SPECTRA	DATE:-	09.1	2.2023

USG BOTH BREAST

5.5mm cyst is seen at 10'O Clock position of the right breast.

Both breast otherwise shows normal parenchymal pattern.

No abnormal ductal dilatation seen.

Skin and subcutaneous tissues are normal.

No abnormal vascularity seen on both sides.

Bilateral subareolar regions are unremarkable.

Few small axillary nodes with preserved fatty hilum are seen bilaterally .

Advise: Clinical and lab Correlation.

DR. MONICA CHHABRACONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796 Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM Received : 09/Dec/2023 12:23PM

Reported : 09/Dec/2023 05:28PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA	

Page 1 of 12







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM Received : 09/Dec/2023 12:23PM

Reported : 09/Dec/2023 05:28PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

DELYNCIMENT OF THE EMPLOYEE					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

13.6	g/dL	12-15	CYANIDE FREE COLOUROMETER
44.50	%	40-50	PULSE HEIGHT AVERAGE
4.92	Million/cu.mm	3.8-4.8	Electrical Impedence
90.4	fL	83-101	Calculated
27.6	pg	27-32	Calculated
30.5	g/dL	31.5-34.5	Calculated
14.3	%	11.6-14	Calculated
11,320	cells/cu.mm	4000-10000	Electrical Impedance
(DLC)			
72	%	40-80	Electrical Impedance
20.8	%	20-40	Electrical Impedance
1.3	%	1-6	Electrical Impedance
5.6	%	2-10	Electrical Impedance
0.3	%	<1-2	Electrical Impedance
			•
8150.4	Cells/cu.mm	2000-7000	Calculated
2354.56	Cells/cu.mm	1000-3000	Calculated
147.16	Cells/cu.mm	20-500	Calculated
633.92	Cells/cu.mm	200-1000	Calculated
33.96	Cells/cu.mm	0-100	Calculated
164000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
04	mm at the end of 1 hour	0-20	Modified Westergren
	4.92 90.4 27.6 30.5 14.3 11,320 (DLC) 72 20.8 1.3 5.6 0.3 8150.4 2354.56 147.16 633.92 33.96 164000	4.92 Million/cu.mm 90.4 fL 27.6 pg 30.5 g/dL 14.3 % 11,320 cells/cu.mm (DLC) 72 % 20.8 % 1.3 % 5.6 % 0.3 % 8150.4 Cells/cu.mm 2354.56 Cells/cu.mm 147.16 Cells/cu.mm 633.92 Cells/cu.mm 33.96 Cells/cu.mm 164000 cells/cu.mm 04 mm at the end	4.92 Million/cu.mm 3.8-4.8 90.4 fL 83-101 27.6 pg 27-32 30.5 g/dL 31.5-34.5 14.3 % 11.6-14 11,320 cells/cu.mm 4000-10000 (DLC) 72 % 40-80 20.8 % 20-40 1.3 % 1-6 5.6 % 2-10 0.3 % <1-2

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC MILDLY INCREASED. DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12

SIN No:BED230304505





UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM

Received : 09/Dec/2023 12:23PM

Reported : 09/Dec/2023 03:04PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	0		Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE		Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 3 of 12







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 03:01PM

Received : 09/Dec/2023 05:56PM Reported : 09/Dec/2023 06:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

GLUCOSE, FASTING, NAF PLASMA	86	mg/dL	70-100	GOD - POD
		9,		

Comment:

As per American Diabetes Guidelines, 2023

F			
Fasting Glucose Values in mg/dL	Interpretation		
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	99	mg/dL	70-140	GOD - POD
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 12







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM Received : 09/Dec/2023 04:20PM

Reported : 09/Dec/2023 04:20PM Reported : 09/Dec/2023 05:24PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	4.9	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG),	94	mg/dL	Calculated
WHOLE BLOOD EDTA			

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM

Received : 09/Dec/2023 04:07PM Reported : 09/Dec/2023 05:34PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	271	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	325	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	42	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	229	mg/dL	<130	Calculated
LDL CHOLESTEROL	164	mg/dL	<100	Calculated
VLDL CHOLESTEROL	65	mg/dL	<30	Calculated
CHOL / HDL RATIO	6.45		0-4.97	Calculated

Kindly correlate clinically.

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 12







UHID/MR No : SCHI.0000016666

: SCHIOPV23796 Visit ID

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh

Collected : 09/Dec/2023 11:33AM Received : 09/Dec/2023 04:07PM

Reported : 09/Dec/2023 05:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ADCOEEMI MEDIWHEEL EIILI BOD	V ANNIIAI DILICO	JECK VD//VNCI	ED EEMALE THE D	AN INDIA EV2224
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method
	1100011	• • • • • • • • • • • • • • • • • • • •	2.01.1011.1011.90	

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	1.10	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	1.00	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	21	U/L	9-52	UV with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	122.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.80	g/dL	6.3-8.2	BIURET METHOD
ALBUMIN	4.40	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.40	g/dL	2.0-3.5	Calculated
A/G RATIO	1.29		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 12

SIN No:SE04564959







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM

Received : 09/Dec/2023 04:07PM

Reported : 09/Dec/2023 05:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ADCOEEMI MEDIWHEEL EIILI BOD	V ANNIIAI DILICO	JECK VD//VNCI	ED EEMALE THE D	AN INDIA EV2224
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method
	1100011	• • • • • • • • • • • • • • • • • • • •	2.01.1011.1011.90	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.80	mg/dL	0.5-1.04	Creatinine amidohydrolase	
UREA	21.00	mg/dL	15-36	Urease	
BLOOD UREA NITROGEN	9.8	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	5.60	mg/dL	2.5-6.2	Uricase	
CALCIUM	9.30	mg/dL	8.4 - 10.2	Arsenazo-III	
PHOSPHORUS, INORGANIC	4.10	mg/dL	2.5-4.5	PMA Phenol	
SODIUM	133	mmol/L	135-145	Direct ISE	
POTASSIUM	4.5	mmol/L	3.5-5.1	Direct ISE	
CHLORIDE	103	mmol/L	98 - 107	Direct ISE	

Page 8 of 12







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM Received : 09/Dec/2023 04:07PM

Reported : 09/Dec/2023 04:37PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y ANNUAL PLUS C	HECK ADVANC	ED - FEMALE - TMT - P.	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	29.00	U/L	12-43	Glyclyclycine
(GGT) , SERUM				Nitoranalide

Page 9 of 12









UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM

Received : 09/Dec/2023 04:13PM Reported : 09/Dec/2023 06:08PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.27	ng/mL	0.7-2.04	CLIA	
THYROXINE (T4, TOTAL)	13.47	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	1.560	μIU/mL	0.34-5.60	CLIA	

Comment:

Hor pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 - 3.0		

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 12







UHID/MR No : SCHI.0000016666

Visit ID : SCHIOPV23796

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : zsfggdh Collected : 09/Dec/2023 11:33AM

Received : 09/Dec/2023 03:06PM

Reported : 09/Dec/2023 03:11PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (CUE), URINE			
PHYSICAL EXAMINATION				
COLOUR	YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION	·		·	·
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUI	NT AND MICROSCOPY	•		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 11 of 12







Patient Name

: Miss.TRIPTI JHA

Age/Gender UHID/MR No

Emp/Auth/TPA ID

: 35 Y 3 M 4 D/F : SCHI.0000016666

Visit ID

: SCHIOPV23796

Ref Doctor

: Dr.SELF : zsfggdh

Collected

: 09/Dec/2023 11:33AM

Received

: 09/Dec/2023 03:06PM : 09/Dec/2023 03:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick
			•
URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE	Dipstick

*** End Of Report ***

Result/s to Follow:

LBC PAP TEST (PAPSURE)

Dr. SHWETA GUPTA MBBS,MD (Pathology)

Consultant Pathology

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Page 12 of 12

